
Why Skills-First Leadership Is Replacing the Ivy League Playbook in the C-Suite
The old prestige pyramid—where Ivy League degrees and blue-chip consulting backgrounds paved the way to the CEO seat—is cracking.
Researchers at the National Institutes of Health (NIH) have developed a new polymerase chain reaction (PCR) assay that can diagnose river blindness more easily and accurately than previous methods. The assay is described in a study published in PLoS Neglected Tropical Diseases journal.
River blindness, also known as onchocerciasis, is a parasitic disease that affects over 20 million people worldwide. The disease is caused by a worm called Onchocerca volvulus, which is spread through the bite of black flies.
River blindness can cause various health problems, including skin lesions, itching, and blindness. The disease is most common in Africa, Central and South America, and the Middle East.
The current diagnostic test for river blindness is a skin snip test, which involves removing a small sample of skin and looking for the presence of the parasite. The skin snip test is accurate, but it is also invasive and can be painful.
The new PCR assay developed by NIH researchers is a non-invasive test that can be performed on a blood or urine sample. The assay is also more sensitive than the skin snip test, meaning it is more likely to detect the parasite in infected people.
The NIH researchers believe that the new PCR assay could revolutionize the diagnosis of river blindness. The assay could make diagnosing the disease in endemic areas easier and more accurate and could also be used to monitor the effectiveness of treatment programs.
NIH researchers have developed a new PCR assay that can be used to diagnose river blindness more easily and accurately than previous methods. The assay could revolutionize the diagnosis of river blindness in endemic areas.
The old prestige pyramid—where Ivy League degrees and blue-chip consulting backgrounds paved the way to the CEO seat—is cracking.
Loud leaders once ruled the boardroom. Charisma was currency. Big talk drove big valuations.
But the CEOs who make history in downturns aren’t the ones with the deepest cuts
Companies invest millions in leadership development, yet many of their best executives leave within a few years. Why?
The most successful business leaders don’t just identify gaps in the market; they anticipate future needs before anyone else.
With technological advancements, shifting consumer expectations, and global interconnectedness, the role of business leaders
Maushum Basu is a visionary leader who inspires his team with a clear, compelling purpose. Unafraid to take calculated risks, he understands that growth often stems from change and innovation. His deep commitment to both Airia Brands, Inc.
When speaking with Martin Paquette, one thing is immediately apparent: he’s honest. His transparency is refreshing. While many shy away from such vulnerability, Paquette sees it as a force to reckon with. The incredible emotional intelligence speaks to years of looking within—it’s also what allows him to acknowledge his mistakes gracefully and use them as opportunities to innovate.
Marina Charriere, CEO of Star Drug Testing Services, Star Drug Testing Services (Windsor Park), and First Defence Face Masks go hand in hand. Star is a drug and alcohol testing facility, and First D F M is a face mask company.
Lejjy Gafour, CEO, CULT Food Science Corp. Lejjy is a self-taught entrepreneur and experienced company operator who made his start creating opportunities at the young age of 14, and he has been working, leading, and building businesses ever since.
Leave us a message
Subscribe
Fill the form our team will contact you
Advertise with us
Fill the form our team will contact you